^
Association details:
| Biomarker: | TPM3-NTRK1 fusion |
|---|---|
| Cancer: | Spindle Cell Sarcoma |
| Drug: | Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas
Excerpt:
The patient was a boy aged 12 years at the time of enrollment with a tropomyosin 3 (TPM3)–NTRK1 fusion, localized, poorly classified spindle cell sarcoma...Therefore, the patient initiated treatment with larotrectinib as his first form of anticancer therapy. He achieved a confirmed partial response after 8 cycles of larotrectinib with a 31% reduction in tumor burden.
DOI:
10.1002/cncr.31701
Trial ID:
